Phase II study of induction chemotherapy with gemcitabine and carboplatin (IndGC) followed by paclitaxel and carboplatin with concurrent thoracic radiation (PCRT) for patients with unresectable stage III non-small-cell lung cancer (NSCLC): MCC-13240

Williams, Charles C.; Wagner, Henry; Greenberg, Harry S.; Sharma, Anupama; Hazelton, Todd R.; Walsh, Frank; Cantor, Alan; Simon, George R.; Haura, Eric B.; Bepler, G.

doi:10.1200/jco.2005.23.16_suppl.7307

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The goal of the first study (MCC-13240) was to obtain tumour biopsies under optimal conditions and measure RRM1 and ERCC1 expression to determine whether there is a direct correlation with response to gemcitabine plus carboplatin in patients with locally advanced stages IIIa and IIIb NSCLC [39]. The aim of the second trial (MCC-13208), referred to as the molecular analysis-directed individualized treatment for advanced NSCLC (MADeIT) trial, was to tailor chemotherapy based on the expression of these genes.…”

Section: Rrm1-and Ercc1-based Chemotherapy Selectionmentioning

confidence: 99%

Pharmacogenomics: A reality or still a promise?

Bepler

2006

Lung Cancer

View full text Add to dashboard Cite

Although notable progress has been made in the treatment of non-small-cell lung cancer (NSCLC) in recent years, this disease is still associated with a poor prognosis for most patients. Modern techniques have facilitated the identification of specific genetic factors that may play a role in disease progression and patient response to therapy, prompting research efforts to identify the clinical predictors of outcome for NSCLC. Recent evidence suggests that the application of a pharmacogenomic approach has the potential to greatly improve survival in certain subpopulations of patients with NSCLC, which could profoundly influence the decision-making process used in evolving treatment strategies for this malignancy.

show abstract

Section: Rrm1-and Ercc1-based Chemotherapy Selectionmentioning

confidence: 99%

Pharmacogenomics: A reality or still a promise?

Bepler

2006

Lung Cancer

View full text Add to dashboard Cite

show abstract

“…Full-dose gemcitabine-based combinations have been studied in the induction setting in several trials. The majority of published data is with gemcitabine and cisplatin [14,[19][20][21][22], although there are also published studies of gemcitabine and carboplatin [23][24][25][26][27][28], vinorelbine [29], and triplet therapy with paclitaxel and a platinum agent [30][31][32]. Most studies used two to three cycles of induction.…”

Section: Gemcitabine Given Sequentially After Radiationmentioning

confidence: 99%

“…In studies evaluating the combination of gemcitabine and carboplatin administered before radiation therapy [23][24][25][26][27][28], the gemcitabine doses have ranged from 1000 to 1250 mg/m 2 on days 1 and 8 with the carboplatin dose ranging from AUC of 5.0 to 5.2 on day 1 every 21 days. Response rates ranged from 30% to 65%, which were similar to those in the gemcitabine with cisplatin studies.…”

Section: Gemcitabine Given Sequentially After Radiationmentioning

confidence: 99%

Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art

Mornex

Girard

2006

Annals of Oncology

View full text Add to dashboard Cite

Stage III non-small cell lung cancer (NSCLC) treatment is evolving. There are several choices available regarding which chemotherapy to use and how to optimally combine them with radiotherapy. Gemcitabine (Gemzar, Eli Lilly and Company, Indianapolis, USA) is a chemotherapeutic agent with activity in NSCLC, and preclinical studies have shown that gemcitabine is a potent radiosensitizer. These two characteristics make gemcitabine a potential option when treating patients with stage III NSCLC. This review article describes the efficacy and tolerance of gemcitabine when combined with radiation in those patients. Gemcitabine used concurrently with radiation, as an induction regimen before radiation, and as a consolidation regimen after radiation is reviewed.

show abstract

Phase II study of induction chemotherapy with gemcitabine and carboplatin (IndGC) followed by paclitaxel and carboplatin with concurrent thoracic radiation (PCRT) for patients with unresectable stage III non-small-cell lung cancer (NSCLC): MCC-13240

Cited by 2 publications

References 0 publications

Pharmacogenomics: A reality or still a promise?

Pharmacogenomics: A reality or still a promise?

Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art

Contact Info

Product

Resources

About